Safety and Efficacy of NeuroFlo Technology In Ischemic Stroke (SENTIS)
Safety and Efficacy of NeuroFlo Technology In Ischemic Stroke (SENTIS): A Study of Care Intensity and Outcomes of Neuroflo® (SCION) To compare treatment for ischemic stroke outcome with NeuroFlo plus standard medical management vs. standard medical management alone. Enrollment : 244 patients at 80 US sites, aged 18 years and older, diagnosed with a focal neurological deficit due to ischemia, with a baseline NIHSS between 5 and 18, in whom the NeuroFlo procedure will begin within 14 hours of symptom onset in those patients randomized to treatment.
Neurology (Brain & Nerve)
W. Scott Burgin, MD
Cheryl Weber, RN, MS, CCRC